Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421137 | 1.00 | AKR1C3 (0.51) | AKR1C3AKR1C2KCNQ2AKR1C1PTGS1 | |
| SCHEMBL15326108 | 0.85 | KCNQ2 (0.49) | KCNQ2HDAC4HDAC7HDAC5CNR2 | |
| SCHEMBL6366259 | 0.84 | HDAC4 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL6366254 | 0.84 | HDAC4 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL6366263 | 0.84 | HDAC4 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL30371733 | 0.83 | CNR2 (0.50) | KCNQ2HDAC4HDAC7HDAC5CNR2 | |
| SCHEMBL2864430 | 0.83 | ROCK2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL27953660 | 0.83 | MEN1 (0.48) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL28140050 | 0.82 | KCNQ2 (0.47) | AKR1C3AKR1C2KCNQ2HDAC4HDAC7 | |
| SCHEMBL30216514 | 0.82 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C1PTGS1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118541359-A | Inhibitors of molluscum contagiosum infection and methods of use thereof | 宾夕法尼亚大学董事会 | 2024-08-23 | — | — | CN | disclosed |
| EP-4408833-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023049919-A1 | INHIBITORS OF MOLLUSCUM CONTAGIOSUM INFECTION AND METHODS USING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-103748075-B | 2,3-diphenyl valeronitrile derivant, its preparation method and as herbicide and the purposes of plant growth regulator | 拜耳知识产权有限责任公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| CN-102264734-B | Alkaloid aminoester derivatives and medicinal composition thereof | CHIESI FARMA SPA | 2015-06-17 | — | — | CN | disclosed |
| WO-2013152272-A1 | ΑΖΑ-β-LACTAM COMPOUNDS AND METHODS OF USING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
| US-7776922-B2 | Substituted [(phenylethanoyl)amino]benzamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20080171786-A1 | e.g. 2-(1-Benzothien-2-yl)-5-[(2-phenylbutanoyl)amino]benzamide; interleukin-8 receptor antagonist; antiinflammatory agent, cardiovascular diseases; arteriosclerosis, coronary heart disease, dyslipidemias, myocardial infarction, stroke, restenosis, reperfusion injury, thrombosis, ischemia | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | US | disclosed |
| EP-1814872-A1 | SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES | Bayer HealthCare AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053748-A1 | SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-05-26 | — | — | WO | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1042275-A1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999029657-A1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171786-A1 | e.g. 2-(1-Benzothien-2-yl)-5-[(2-phenylbutanoyl)amino]benzamide; interleukin-8 receptor antagonist; antiinflammatory agent, cardiovascular diseases; arteriosclerosis, coronary heart disease, dyslipidemias, myocardial infarction, stroke, restenosis, reperfusion injury, thrombosis, ischemia | CXCL8, CASP8, TLR8 | AKR1C3 2698/4885AKR1C2 1818/4885KCNQ2 2164/4885 |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | BAD, BAK1, BRDT | AKR1C3 3194/4885AKR1C2 2250/4885KCNQ2 3751/4885 |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | AKR1C3 4377/4885AKR1C2 3730/4885KCNQ2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.